Drug Trial Radar · NCT07644195
Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
14
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Trellis Bioscience LLCIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study in healthy volunteers will provide a basis for evaluation of inhaled TRL1068 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data.
Conditions
- Healthy Volunteer
Interventions
TRL1068, a human monoclonal antibodyDrug
The IP will be in a solution for inhalation at a nominal concentration of 20 mg/mL. The IP will be reconstituted with a formulation buffer to 10 mg/mL/PS20 0.055% and dosed at a fixed dose of 60 mg per dose (volume of 6 mL) to full completion. Placebo will be normal saline. This study will use a marketed nebulizer device, the Aerogen Solo™, which is designed to generate an aerosol to achieve effective levels of TRL1068 in distal airways.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of abnormal physical exam findingsTime frame: 30 days
- Severity of abnormal physical exam findingsTime frame: 30 days
- Incidence of abnormal serum chemistries and hematologyTime frame: 30 days
- Severity of abnormal serum chemistries and hematologyTime frame: 30 days
- Incidence of abnormal vital signs (temperature)Time frame: 30 days
- Severity of abnormal vital signs (temperature)Time frame: 30 days
- Incidence of abnormal vital signs (blood pressure)Time frame: 30 days
- Severity of abnormal vital signs (blood pressure)Time frame: 30 days
- Incidence of abnormal vital signs (heart rate)Time frame: 30 days
- Severity of abnormal vital signs (heart rate)Time frame: 30 days
- Incidence and Severity of Adverse EventsTime frame: 30 days
- Incidence of Serious Adverse EventsTime frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.